drugset / Trial / NCT06414356

The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic Pain and PTSD

NCT06414356

Phase 4 Recruiting 30 enrolled Margaux M. Salas, PhD
RandomizedFactorialDouble-blindTreatment

Summary

This study is aimed to evaluate outpatient ketamine infusion within a military chronic neuropathic pain population and its effect on PTSD. Currently, this is a pilot study with 30 participants. Participants will be randomized to (1) a moderate dose ketamine, (2) moderate dose ketamine +Mg, or (3) a magnesium control group. Participants will complete self-reported pain and PTSD questionnaires throughout the \~24-week study period. The outlined strategy will provide evidence for the utility of ketamine in neuropathic pain management and pain associated comorbidities within a military population.

Timeline

Start
2024-10-02
Primary completion
2025-04
Completion
2027-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 0.5 mg/kg Intravenous
Subject Magnesium Sulfate Other / unclassified 3 g Intravenous